Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
Authors
Cody Eslinger
Department of Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ
Cody Eslinger , Alyssa McGary , Daniel Walden , Oluwadunni Eunice Emiloju , Daniel H. Ahn , Bassam Bassam Sonbol , Tanios S. Bekaii-Saab , Mojun Zhu , Joleen M. Hubbard , Christina Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 175)
DOI
10.1200/JCO.2024.42.3_suppl.175
Abstract #
175
Poster Bd #
L3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Prospective correlation between clinical and pathologic criteria identification of lynch syndrome (LS) in endometrial carcinoma (EC) patients and relapse.
First Author: Ignacio Romero
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer.
First Author: David Viñal
Poster
2020 ASCO Virtual Scientific Program
Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy (P) after FDA approval.
First Author: Tamara Snow
Poster
2020 ASCO Virtual Scientific Program
Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI).
First Author: Shahla Bari